CG Oncology (CGON) Interest & Investment Income (2023 - 2026)

CG Oncology (CGON) has 4 years of Interest & Investment Income data on file, last reported at $6.3 million in Q1 2026.

• Quarterly Interest & Investment Income fell 18.83% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.5 million (down 1.23% YoY) and the FY2025 annual result came in at $29.9 million, up 12.42% from the prior year.
• Interest & Investment Income declined to $6.3 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q3 2024 to a low of $771000.0 in Q2 2023.
• A 4-year average of $5.4 million and a median of $6.3 million in 2026 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2024 — Interest & Investment Income jumped 800.52% — and 2026, when it decreased 18.83%.
• Tracing CGON's Interest & Investment Income over 4 years: stood at $2.8 million in 2023, then jumped by 122.72% to $6.2 million in 2024, then climbed by 19.2% to $7.4 million in 2025, then declined by 15.53% to $6.3 million in 2026.
• The last three Interest & Investment Income figures came in at $6.3 million (Q1 2026), $7.4 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.